Skip to Main Content

Gerald I Shulman, MD, PhD, MACP, MACE, FRCP

George R. Cowgill Professor of Medicine (Endocrinology) and Professor of Cellular And Molecular Physiology
DownloadHi-Res Photo

Additional Titles

Co-Director, Yale Diabetes Research Center, Internal Medicine

Director, Internal Medicine

About

Titles

George R. Cowgill Professor of Medicine (Endocrinology) and Professor of Cellular And Molecular Physiology

Co-Director, Yale Diabetes Research Center, Internal Medicine; Director, Internal Medicine

Biography

Dr. Shulman is the George R. Cowgill Professor of Medicine and Cellular & Molecular Physiology at Yale. He is also an Investigator Emeritus of the Howard Hughes Medical Institute and Co-Director of the Yale Diabetes Research Center. Dr. Shulman has pioneered the use of magnetic resonance spectroscopy combined with mass spectrometry to non-invasively examine intracellular glucose and fat metabolism in humans and transgenic rodent models that have led to several paradigm shifts in our understanding of type 2 diabetes (T2D), including the molecular mechanisms by which ectopic lipid promotes liver and muscle insulin resistance, as well as developing new drugs for the treatment of T2D, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Dr. Shulman is the recipient of the Stanley J. Korsymeyer Award from the American Society for Clinical Investigation, the Outstanding Clinical Investigator Award from the Endocrine Society, the Solomon Berson Award from the American Physiological Society, the Banting Medal for Lifetime Scientific Achievement from the American Diabetes Association and the Manpei-Suzuki International Prize for Diabetes Research and the EASD-Lilly Centennial Anniversary Prize for Landmark Achievements in the Pathogenesis of Diabetes. Dr. Shulman is a Fellow of the American Association for the Advancement of Science, Inaugural Fellow of the American Physiological Society and he has been elected to the American Society for Clinical Investigation, the Association of American Physicians, the National Academy of Medicine, the American Academy of Arts and Sciences and the National Academy of Sciences.

Appointments

Education & Training

Research Fellow
Massachusetts General Hospital/Harvard Medical School (1984)
Resident
Duke University Medical Center (1981)
MD
Wayne State University (1979)
PhD
Wayne State University, Physiology (1979)

Research

Overview

Shulman Lab

Mitochondria play an essential role in energy conversion and nearly all of the different components of food pass through the mitochondria for the generation of energy yet surprisingly little is known regarding the regulation of these anaplerotic and cataplerotic mitochondrial fluxes in vivo and the potential role they have in causing rare and common metabolic diseases such as type 2 diabetes and related cardiometabolic diseases.

The Shulman Lab is interested in: 1) Understanding the hormonal regulation of mitochondrial fluxes in vivo using novel NMR and LC-MS/MS methods (e.g. PINTA, Q-Flux) which we have recently developed to measure mitochondrial oxidative and anaplerotic fluxes in an organ (e.g. liver, muscle, renal cortex, brain) specific manner for the first time 2) Understanding the role of dysregulated mitochondrial fluxes in the pathogenesis of type 2 diabetes, lipodystrophy, polycystic kidney disease as well as other rare inherited metabolic diseases, 3) Development of novel agents to promote: a) liver-targeted mitochondrial uncoupling, b) alterations of intracellular NAD+ metabolism, c) alterations of intracellular CoA formation, for the treatment of, diabetes, atherosclerosis, aging and inherited diseases of lipid metabolism, 4) Assess the impact of SGLT2 inhibitors on myocardial and atrial mitochondrial metabolism and elucidate the mechanism for their cardioprotective effects, 5) Understand the role of cytosolic and mitochondrial Ca++ in the regulation of hepatic mitochondrial oxidation and gluconeogenesis and 6) Development of additional novel NMR, LC/MS/MS and GC/MS methodology to assess in vivo intracellular flux rates of glucose, amino acid and fatty acid metabolism and their applications to humans and transgenic/gene knockout rodent models of metabolic diseases.

Selected Publications

• Shulman, GI. Role of ectopic fat in insulin resistance, dyslipidemia and cardiometabolic disease. N Engl J Med. 2014;371(12)1131-1141.

• Perry RJ, Camporez JP, Kursawe R, Titchenell PM, Zhang D, Perry CJ, Jurczak MJ, Abudukadier A, Han MS, Zhang XM Ruan HB, Yang, X, Caprio, S, Kaech, SM, Sul, HS, Birnbaum MJ, Davis RJ, Cline GW, Petersen KF, Shulman GI. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell. 2015;(160)745-58.

• Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, Prigaro BJ, Wood JL, Bhanot S, MacDonald MJ, Jurczak, M, Camporez JP, Lee HY, Cline GW, Samuel VT, Kibbey RG, Shulman GI. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014;510:542-546

• Perry RJ, Zhang D, Zhang XM, Boyer JL, Shulman GI. Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats. Science. 2015;347(6227)1253-56.

• Petersen KF, Befroy DE, Dufour S, Rothman DL, Shulman GI. Direct assessment of hepatic mitochondrial oxidation and pyruvate cycling in nonalcoholic fatty liver disease by 13C magnetic resonance spectroscopy. Cell Metab. 2016;24(1)167-71,

• Petersen MC, Madiraju AK, Gassaway BM, Marcel M, Nasiri AR, Butrico G, Marcucci MJ, Zhang D, Abudukadier A, Zhang XM, Philbrick W, Hubbard SR, Jurczak MJ, Samuel VT, Rinehart J, Shulman GI. Insulin receptor Thr1160 phosphorylation mediates lipid-induced hepatic insulin resistance. J Clin Invest, 2016;1-11.

• Perry RJ, Peng L, Abudukadier A, Kennedy L, Cline GW, Shulman GI. Mechanism for leptin’s acute insulin-independent effect to reverse diabetic ketoacidosis. J Clin Invest. 2017;127(2)657-669.

• Perry RJ, Wang Y, Cline GW, Rabin-Court A, Song JD, Dufour S, Zhang XM, Petersen KF, Shulman GI. Leptin mediates a glucose-fatty acid cycle to maintain glucose homeostasis in starvation. Cell. 2018; 172 (1-2) 234-248.

• Roden M, Shulman GI. The Integrative Biology of Type-2 Diabetes. Nature. 576 (7785): 51-60.

• Petersen KF, Dufour S, Cline GW, Shulman GI. Regulation of Hepatic Mitochondrial Oxidation by Glucose-Alanine Cycling During Starvation in Humans. J Clin Invest. 2019; 129 (11): 4671-467.

• Goedeke L, Peng L, Montalvo-Romeral V, Butrico G, Dufour S, Zhang XM, Perry RJ, Cline GW, Kievit P, Chng K, Petersen KF, Shulman GI. Controlled-release Mitochondrial Protonophore (CRMP) Reverses Dyslipidemia and Hepatic Steatosis in Dysmetabolic Nonhuman Primates. Science Translational Medicine. 2019; 11 (512)

• Perry RJ, Zhang D, Guerra MT, Brill AL, Goedeke L, Nasiri AR, Rabin-Court A, Wang Y, Peng L, Dufour S, Zhang Y, Zhang XM, Butrico G, Toussaint K, Nozaki Y, Cline GW, Petersen KF, Nathanson MH, Ehrlich BE, Shulman GI. Glucagon Stimulates Gluconeogenesis by InsP3R-I Mediated Hepatic Lipolysis. Nature. 2020; 579(7798):279-283.

• Hubbard BT, LaMoia TE, Goedeke L, Gaspar RC, Galsgaard KD, Kahn M, Mason GF, Shulman GI. Q-Flux: A Novel Method to Assess Rates of Hepatic Mitochondrial Succinate Dehydrogenase, Methylmalonyl-CoA Mutase, and Glutaminase Fluxes in vivo. Cell Metabolism. 2023; 35 (1): 212-226. PMID: 36516861.

Medical Subject Headings (MeSH)

Analytical, Diagnostic and Therapeutic Techniques and Equipment; Chemicals and Drugs; Endocrine System Diseases; Insulin Resistance; Molecular Biology; Non-alcoholic Fatty Liver Disease; Physiology

Research at a Glance

Yale Co-Authors

Frequent collaborators of Gerald I Shulman's published research.

Publications

2024

Clinical Trials

Current Trials

Academic Achievements & Community Involvement

  • activity

    Journal of Clinical Investigation

  • activity

    Current Diabetes Reports

  • activity

    Cell Metabolism

  • activity

    Clinical and Translational Science

  • activity

    Science Translational Medicine

Clinical Care

Overview

Gerald I. Shulman, MD, PhD, specializes in endocrinology and metabolism. He is the co-director of the Yale Diabetes Research Center.

Dr. Shulman's research focuses on various aspects of metabolism, including liver function, insulin resistance, lipid metabolism, and inflammation. His work explores genetic factors affecting liver function, fat production, and energy use, and the differences between healthy and unhealthy obesity.

A recipient of the Banting Medal for Lifetime Scientific Achievement, the Solomon Berson Award, and the Manpei Suzuki International Prize for Diabetes Research, Dr. Shulman is a George R. Cowgill Professor of Medicine (endocrinology) and professor of cellular and molecular physiology at Yale School of Medicine.

Clinical Specialties

Internal Medicine; Endocrinology

Board Certifications

  • Endocrinology & Metabolism

    Certification Organization
    AB of Internal Medicine
    Latest Certification Date
    1985
    Original Certification Date
    1985
  • Internal Medicine

    Certification Organization
    AB of Internal Medicine
    Original Certification Date
    1982

Get In Touch

Contacts

Academic Office Number
Appointment Number

Administrative Support

Locations

  • Patient Care Locations

    Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.